DE19945302A1 - Biphenylderivate als NHE-3-Inhibitoren - Google Patents

Biphenylderivate als NHE-3-Inhibitoren

Info

Publication number
DE19945302A1
DE19945302A1 DE19945302A DE19945302A DE19945302A1 DE 19945302 A1 DE19945302 A1 DE 19945302A1 DE 19945302 A DE19945302 A DE 19945302A DE 19945302 A DE19945302 A DE 19945302A DE 19945302 A1 DE19945302 A1 DE 19945302A1
Authority
DE
Germany
Prior art keywords
biphenyl
compounds
formula
nhe
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19945302A
Other languages
German (de)
English (en)
Inventor
Dieter Dorsch
Peter Raddatz
Norbert Beier
Claudia Wilm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to DE19945302A priority Critical patent/DE19945302A1/de
Priority to BR0014199-2A priority patent/BR0014199A/pt
Priority to PL00355097A priority patent/PL355097A1/xx
Priority to CZ2002815A priority patent/CZ2002815A3/cs
Priority to CNA008131600A priority patent/CN1555356A/zh
Priority to AU76497/00A priority patent/AU7649700A/en
Priority to CA002387529A priority patent/CA2387529A1/fr
Priority to SK334-2002A priority patent/SK3342002A3/sk
Priority to KR1020027003735A priority patent/KR20020033818A/ko
Priority to MXPA02003087A priority patent/MXPA02003087A/es
Priority to HU0202891A priority patent/HUP0202891A3/hu
Priority to JP2001524962A priority patent/JP2004500338A/ja
Priority to EP00965915A priority patent/EP1214291A1/fr
Priority to PCT/EP2000/008616 priority patent/WO2001021582A1/fr
Publication of DE19945302A1 publication Critical patent/DE19945302A1/de
Priority to NO20021407A priority patent/NO20021407L/no
Priority to ZA200203095A priority patent/ZA200203095B/xx
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE19945302A 1999-09-22 1999-09-22 Biphenylderivate als NHE-3-Inhibitoren Withdrawn DE19945302A1 (de)

Priority Applications (16)

Application Number Priority Date Filing Date Title
DE19945302A DE19945302A1 (de) 1999-09-22 1999-09-22 Biphenylderivate als NHE-3-Inhibitoren
SK334-2002A SK3342002A3 (en) 1999-09-22 2000-09-04 Biphenyl derivatives used as nhe-3 inhibitors
HU0202891A HUP0202891A3 (en) 1999-09-22 2000-09-04 Biphenyl derivatives used as nhe-3 inhibitors and pharmaceutical compositions containing them
CZ2002815A CZ2002815A3 (cs) 1999-09-22 2000-09-04 Deriváty bifenylu jakoľto NHE-3 inhibitory
CNA008131600A CN1555356A (zh) 1999-09-22 2000-09-04 作为nhe-3抑制剂的双酚衍生物
AU76497/00A AU7649700A (en) 1999-09-22 2000-09-04 Biphenyl derivatives used as nhe-3 inhibitors
CA002387529A CA2387529A1 (fr) 1999-09-22 2000-09-04 Derives biphenyliques utilises comme inhibiteurs de nhe-3
BR0014199-2A BR0014199A (pt) 1999-09-22 2000-09-04 Derivados de bifenila como inibidores de nhe-3
KR1020027003735A KR20020033818A (ko) 1999-09-22 2000-09-04 Ｎｈｅ-3 저해제로서 사용되는 비페닐 유도체
MXPA02003087A MXPA02003087A (es) 1999-09-22 2000-09-04 Derivados de bifenilo como inhibidores del nhe-3.
PL00355097A PL355097A1 (en) 1999-09-22 2000-09-04 Biphenyl derivatives used as nhe-3 inhibitors
JP2001524962A JP2004500338A (ja) 1999-09-22 2000-09-04 Ｎｈｅ−３阻害剤として用いられるビフェニル誘導体
EP00965915A EP1214291A1 (fr) 1999-09-22 2000-09-04 Derives biphenyliques utilises comme inhibiteurs de nhe-3
PCT/EP2000/008616 WO2001021582A1 (fr) 1999-09-22 2000-09-04 Derives biphenyliques utilises comme inhibiteurs de nhe-3
NO20021407A NO20021407L (no) 1999-09-22 2002-03-21 Bifenylderivater anvendt som NHE-3-inhibitorer
ZA200203095A ZA200203095B (en) 1999-09-22 2002-04-18 Biphenyl derivatives used as NHE-3 inhibitors.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19945302A DE19945302A1 (de) 1999-09-22 1999-09-22 Biphenylderivate als NHE-3-Inhibitoren

Publications (1)

Publication Number Publication Date
DE19945302A1 true DE19945302A1 (de) 2001-03-29

Family

ID=7922831

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19945302A Withdrawn DE19945302A1 (de) 1999-09-22 1999-09-22 Biphenylderivate als NHE-3-Inhibitoren

Country Status (16)

Country Link
EP (1) EP1214291A1 (fr)
JP (1) JP2004500338A (fr)
KR (1) KR20020033818A (fr)
CN (1) CN1555356A (fr)
AU (1) AU7649700A (fr)
BR (1) BR0014199A (fr)
CA (1) CA2387529A1 (fr)
CZ (1) CZ2002815A3 (fr)
DE (1) DE19945302A1 (fr)
HU (1) HUP0202891A3 (fr)
MX (1) MXPA02003087A (fr)
NO (1) NO20021407L (fr)
PL (1) PL355097A1 (fr)
SK (1) SK3342002A3 (fr)
WO (1) WO2001021582A1 (fr)
ZA (1) ZA200203095B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
WO2010025856A1 (fr) * 2008-09-02 2010-03-11 Sanofi-Aventis Aminoindanes substitués, leurs analogues, et leur utilisation pharmaceutique
US8716470B2 (en) 2011-03-15 2014-05-06 Astellas Pharma Inc. Guanidine compound

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10163239A1 (de) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament
US7049333B2 (en) 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
US20050054705A1 (en) 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
DE10304374A1 (de) 2003-02-04 2004-08-05 Aventis Pharma Deutschland Gmbh Neue substituierte 2-Aminoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10341240A1 (de) 2003-09-08 2005-04-07 Aventis Pharma Deutschland Gmbh Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE102005001411A1 (de) 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
WO2009006066A2 (fr) 2007-06-28 2009-01-08 Sanofi-Aventis U.S. Llc Procédé de préparation de composés à base de benzimidazole thiénylamine et leurs dérivés utiles en tant qu'inhibiteurs de type 3 d'échangeur sodium-protons
AU2009334511C1 (en) 2008-12-31 2016-08-18 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal
CN103012200B (zh) * 2011-09-20 2014-12-17 北京大学 具有β-分泌酶抑制功能的化合物及其制备方法与应用
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
BR112015003527A2 (pt) 2012-08-21 2017-07-04 Ardelyx Inc compostos e métodos para inibição de antiporte mediado por nhe no tratamento de desordens associadas à retenção de fluido ou sobrecarga de sal e desordens do trato gastrointestinal
SI2983667T1 (sl) 2013-04-12 2019-09-30 Ardelyx, Inc. Spojine za vezavo NHE3 in metode za zaviranje transporta fosfata
RU2703456C2 (ru) 2014-07-25 2019-10-17 Тайсо Фармасьютикал Ко., Лтд. Фенилтетрагидроизохинолиновое соединение, замещенное гетероарилом
MX2019008170A (es) 2017-01-09 2020-02-07 Ardelyx Inc Compuestos útiles para tratar transtornos del tracto gastrointestinal.
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.
EP3661945B1 (fr) 2017-08-04 2024-04-03 Ardelyx, Inc. Dérivés d'acide glycyrrhétinique de traitement de l'hyperkaliémie
AU2020218255A1 (en) 2019-02-07 2021-09-09 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548812A1 (de) * 1995-12-27 1997-07-03 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
DE19622222A1 (de) * 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
DE19737224A1 (de) * 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen
DE19819548A1 (de) * 1998-04-30 1999-11-04 Merck Patent Gmbh Biphenylderivate

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
WO2010025856A1 (fr) * 2008-09-02 2010-03-11 Sanofi-Aventis Aminoindanes substitués, leurs analogues, et leur utilisation pharmaceutique
RU2522586C2 (ru) * 2008-09-02 2014-07-20 Санофи-Авентис Замещенные аминоинданы и их аналоги, и их применение в фармацевтике
US8822449B2 (en) 2008-09-02 2014-09-02 Sanofi Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
US9550788B2 (en) 2008-09-02 2017-01-24 Sanofi Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
US8716470B2 (en) 2011-03-15 2014-05-06 Astellas Pharma Inc. Guanidine compound
US9051283B2 (en) 2011-03-15 2015-06-09 Astellas Pharma Inc. Guanidine compound
US9556160B2 (en) 2011-03-15 2017-01-31 Astellas Pharma Inc. Guanidine compound

Also Published As

Publication number Publication date
CA2387529A1 (fr) 2001-03-29
CN1555356A (zh) 2004-12-15
JP2004500338A (ja) 2004-01-08
PL355097A1 (en) 2004-03-22
KR20020033818A (ko) 2002-05-07
SK3342002A3 (en) 2002-07-02
MXPA02003087A (es) 2003-08-20
BR0014199A (pt) 2002-05-21
WO2001021582A1 (fr) 2001-03-29
ZA200203095B (en) 2003-09-23
NO20021407D0 (no) 2002-03-21
CZ2002815A3 (cs) 2002-08-14
HUP0202891A3 (en) 2003-11-28
NO20021407L (no) 2002-03-21
EP1214291A1 (fr) 2002-06-19
HUP0202891A2 (hu) 2003-02-28
AU7649700A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
DE19945302A1 (de) Biphenylderivate als NHE-3-Inhibitoren
EP0496378B1 (fr) Dérivés biphényliques, médicaments contenant ces composés et procédés pour leur préparation
DE60221569T2 (de) Acrylsulfonamidderivate zur verwendung als ccr3-antagonisten bei der behandlung von inflammatorischen und immunologischen erkrankungen
DE10019062A1 (de) 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren
DE19548709A1 (de) Tyrosinderivate
DE10163992A1 (de) 4-Aryl-chinazoline
WO1994017035A1 (fr) Derives d'amino-acides, medicaments contenant ces composes et procede permettant de les preparer
LV10427B (en) A method for producing of benzoyl-guanidine
JPH08503466A (ja) 置換アミジノ化合物、それらの製法および治療方法
DE10110749A1 (de) Substituierte Aminodicarbonsäurederivate
DE19544687A1 (de) Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE10015248A1 (de) Bisamidino-Verbindungen als NHE-3 Inhibitoren
DE10043667A1 (de) 2-Guanidino-4-aryl-chinazoline
DE69102503T2 (de) N-Phenyl-N'-alkylsulfonylharnstoffe, Verfahren zu ihrer Herstellung und diese enthaltende Antitumorzusammensetzungen.
DE19900471A1 (de) Imidazo[4,5c]-pyridin-4-on-derivate
DE69914614T2 (de) Ungesättigte hydroximsäurederivate als parp inhibitoren
WO1999057096A1 (fr) Derives diphenyliques
WO2003051866A1 (fr) 2-guanidino-4-heterocyclyl-chinazoline
EP0725064A1 (fr) Utilisation d'amides des acides phénylcyclohexylcarboxyliques
DE60114597T2 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
DE19939980A1 (de) Inhibitoren des Integrins alphavbeta¶3¶
EP1999113B1 (fr) 1-amino-4-phényl-dihydroisoquinoléines substituées, procédé de préparation, utilisation en tant que médicament et médicament les contenant
EP1999112B1 (fr) 2-amino-4-phényl-dihydroquinoléines substituées, procédé de préparation, utilisation en tant que médicament et médicament les contenant
DE19939981A1 (de) Neue Inhibitoren des Integrins alphavß3
DE19916837A1 (de) Dibenzoazulenderivate

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee